2.70
-0.37%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Apimeds Pharmaceuticals US
From its filings with the US Securities and Exchange Commission
Apimeds Pharmaceuticals US is based in Matawan, New Jersey and is incorporated in Delaware. Its shares trade on NYSE under the ticker APUS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $6.0m. At that date it held total assets of $164.2m and shareholders' equity of $153.3m.
The Closing occurred simultaneously with the execution and delivery of the Merger Agreement on the Closing Date.
Application. If such approval is not obtained, the Preferred Stock Conversion and the Notes Conversion will not be completed.
The Apimeds Korea Phase III OA Trial (330 patients) was completed in 2018, and displayed no serious adverse events.
3,194 patients from 2003 through 2009, with no serious adverse events or negative safety signals.
Quoted from its 10-K, filed 4 May 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 9 May 2025
- Employees
- 2
- Website
- apimedsus.com ↗
- Head office
- 100 MATAWAN RD, MATAWAN, NJ, 07747
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. Christopher KimChairman of the Board, Chief Medical Officer, since 2023$96,000
- Mr. Erik EmersonChief Executive Officer, Director$300,000
- Mr. Erick FrimChief Financial Officer
- Mr. Jakap KooDirector
- Ms. Elona KoganIndependent Director
- Ms. Carol O'DonnellIndependent Director
- Dr. Bennett WeintraubIndependent Director
- Dr. Hankil YoonIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Apimeds Pharmaceuticals US Inc's Apitox is developed as a potential osteoarthritis treatment for knee pain patients who failed conservative therapy.
- The company's headquarters in Matawan, New Jersey, provides a stable operational base for its biotechnology operations.
- Apimeds' focus on Apitox, a bee venom-based toxin, differentiates it within the Health Care sector.
Weaknesses
- Apimeds Pharmaceuticals US Inc has only 2 employees, limiting its operational capacity.
- The company's IPO is scheduled for May 9, 2025, indicating it is still in a pre-revenue stage.
- Apitox is currently in clinical development, not yet approved for market use.
Opportunities
- Apimeds can leverage the growing market for osteoarthritis treatments in the Health Care sector.
- The company's focus on Apitox as a treatment for knee pain patients may attract partnerships with larger pharmaceutical firms.
- The upcoming IPO in May 2025 could provide capital for further clinical development of Apitox.
Threats
- Apitox's clinical development stage poses a risk of failure in achieving regulatory approval.
- The biotechnology industry faces high competition for osteoarthritis treatments.
- The small employee count of 2 may hinder the company's ability to navigate regulatory challenges.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.